Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma

ABSTRACT Background Multiple myeloma (MM) is a blood cancer marked by the abnormal clonal growth of plasma cells. Hypoxia plays a critical role in the progression and treatment resistance of MM. Aims This study investigates the expression of B‐cell/CLL lymphoma 2 (BCL2) family genes. We also investi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Seiichi Okabe, Yuya Arai, Yuko Tanaka, Akihiko Gotoh
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Cancer Reports
Subjects:	BCL2 hypoxia myeloma selinexor venetoclax
Online Access:	https://doi.org/10.1002/cnr2.70249
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
by: Kereshmeh Tasbihi, et al.
Published: (2025-03-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
by: Junying Wang, et al.
Published: (2025-01-01)

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review
by: Chen B, et al.
Published: (2025-04-01)

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges
by: Ziyu Qie, et al.
Published: (2025-05-01)

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
by: Omar Alhalabi, et al.
Published: (2025-02-01)

Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease
by: Ayaka Ohashi, et al.
Published: (2025-05-01)

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations
by: Jie Yang, et al.
Published: (2025-09-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Successful experience of venetoclax in the treatment of refractory primary plasma cell leukemia
by: I. V. Cherkashina, et al.
Published: (2025-03-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

EFFECTIVENESS OF VENETOСLAX IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (LITERATURE REVIEW)
by: V. V. Strugov, et al.
Published: (2018-02-01)

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method
by: Suhyun Lee, et al.
Published: (2025-07-01)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
by: Jing Li, et al.
Published: (2025-05-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects
by: Abdullah AlZahrani, et al.
Published: (2024-12-01)

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition
by: Pei-Hong Wang, et al.
Published: (2025-05-01)

The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination
by: Tao Wang, et al.
Published: (2025-03-01)

The impact of N-acetylcysteine on hypoxia-induced testicular apoptosis in male rats: TUNEL and IHC findings
by: Majid Shokoohi, et al.
Published: (2024-11-01)

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation
by: Manman Deng, et al.
Published: (2025-07-01)

Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01)

A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies
by: Yang J, et al.
Published: (2025-05-01)

Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01)

Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia
by: Yi Wang, et al.
Published: (2025-04-01)

Venetoclax – The game-changer in hematology
by: Tanmoy Kumar Mandal, et al.
Published: (2020-01-01)

Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report
by: Kavya Sudireddy, et al.
Published: (2025-01-01)

Preventing and managing the toxicities associated with the combination therapy of ibrutinib and venetoclax in chronic lymphocytic leukaemia
by: Elżbieta Iskierka-Jażdżewska, et al.
Published: (2025-01-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

The Sec61 translocon is a therapeutic vulnerability in multiple myeloma
by: Antoine Domenger, et al.
Published: (2022-01-01)

Durable response to venetoclax, azacytidine, and ruxolitinib in chronic-phase myelofibrosis resistant to ruxolitinib: a case report and literature review
by: Xiaohong Liu, et al.
Published: (2025-08-01)

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation
by: Hiroshi Ureshino, et al.
Published: (2025-05-01)

Effects of ibrutinib and venetoclax on the expression of immune checkpoint molecules in leukemic blasts of patients with acute lymphoblastic leukemia
by: Armin Dozandeh-Jouybari, et al.
Published: (2025-06-01)

Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia
by: Yu Cui, et al.
Published: (2024-12-01)

Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia
by: Kendall Diebold, et al.
Published: (2025-06-01)

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study
by: Jie-Fei Bai, et al.
Published: (2025-06-01)

ARNT/HIF‐1β links high‐risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma
by: Chuan Wu, et al.
Published: (2018-08-01)

Chinese population may require further venetoclax dose reduction beyond guidelines when combined with voriconazole: real-world evidence from China
by: Rongrong Wang, et al.
Published: (2025-05-01)